课题基金 / 基金详情

项目摘要

项目成果

Elizabeth J Shpall的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):脐带血(CB)越来越多地用于缺乏兄弟姐妹或非亲属供体的移植患者恢复造血功能。CB移植(CBT)的一个主要缺点是低细胞剂量导致中性粒细胞和血小板植入延迟,以及植入失败率高。该资助的一个主要假设是体外扩增的CB祖细胞将比未处理的CB祖细胞提供更快的造血重建和更少的植入失败。在上一次RO1资助期间进行的两项临床CB扩展试验中,CD133+祖细胞被分离并在液体培养系统中体外培养,目标是承诺或更原始的造血祖细胞。在这些连续的试验中,可以看到更快的移植时间的趋势,但CD34+祖细胞的显著损失发生了。为了避免需要阳性选择,导致CD34+细胞的大量损失,我们已经开发了一种替代方法,包括骨髓源间充质干细胞(MSC)与CB单个核细胞(MNC)的体外共培养。我们假设MSC作为造血“生态位”的替代物,将比目前的液体悬浮培养系统提供更合适的微环境来扩展具有谱系承诺的CB造血祖细胞。随着目前CB扩展试验的临近完成,这一竞争性更新申请将侧重于MSC共培养中CB扩展的临床评估,其长期目标是改善CBT患者的中性粒细胞和血小板植入。虽然低细胞剂量显然是CBT的主要限制,但许多研究者也报道了CB细胞归巢到骨髓的缺陷。因此,可以想象的是,即使有最佳的体外扩张,不充分的归巢可能会限制植入的速度,这是本提案的目标。归巢缺陷归因于骨髓微血管表达的与P-和/或e -选择素结合的细胞表面分子的低水平聚焦。这种相互作用是造血祖细胞向骨髓募集的关键组成部分。我们假设增加CB细胞表面聚焦水平将改善与选择素的相互作用,从而改善归巢和植入。目的3将评估用focusyltransferase修饰未操作和扩增的CB祖细胞,作为促进其募集到骨髓的手段。
英文摘要
DESCRIPTION (provided by applicant): Umbilical cord blood (CB) is used increasingly to restore hematopoiesis in transplant patients lacking sibling, or unrelated donors. A major disadvantage of CB transplantation (CBT) is the low cell dose with resultant delays in neutrophil and platelet engraftment, as well as a high rate of engraftment failure. A major hypothesis of this grant is that ex vivo-expanded CB progenitors will provide more rapid hematopoietic reconstitution and less engraftment failure than unmanipulated CB. In the two clinical CB expansion trials conducted during the last RO1 funding period, CD133+ progenitors were isolated and cultured ex vivo in a liquid culture system targeting committed, or more primitive hematopoietic progenitors. In those sequential trials, trends in faster time to engraftment were seen, but significant losses of CD34+ progenitors occurred. To avoid the need for positive selection, which results in a substantial loss of CD34+ cells, we have developed an alternative approach that involves the ex vivo co-culture of CB mononuclear cells (MNC) with bone marrow-derived mesenchymal stem cells (MSC). We hypothesize that MSC, by functioning as a surrogate hematopoietic 'niche', will provide a more suitable microenvironment for the expansion of lineage-committed CB hematopoietic progenitors than afforded by current liquid suspension culture systems. As accrual to the current CB expansion trials nears completion, this competitive renewal application will focus on the clinical evaluation of CB expansion in MSC co-cultures, with the long-term goal of improving neutrophil and platelet engraftment in CBT patients. Although a low cell dose is clearly the chief limitation of CBT, a number of investigators have also reported a deficit in the homing of CB cells to the marrow. Thus, it is conceivable that even with optimal ex vivo expansion, inadequate homing may limit the rapidity of engraftment which is the goal of this proposal. The homing defect has been attributed to low levels of fucosylation of cell surface molecules responsible for binding to P- and/or E-selectins expressed by the marrow microvasculature. This interaction is a key component of the recruitment of hematopoietic progenitors to the marrow. We hypothesize that increasing the level of CB cell surface fucosylation will improve interactions with selectins, thereby improving homing and engraftment. Aim 3 will evaluate the modification of unmanipulated and expanded CB progenitor cells with a fucosyltransferase, as a means to facilitate their recruitment to the marrow.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SPORE University of Texas M. D. Anderson Cancer Center-Leukemia
Cord Blood Graft Engineering to Improve Engraftment and Reduce GVHD
Cord Blood Expansion and Homing to Improve Engraftment
Administrative Core
海外基金